Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 325 | 34 | 289 |
| Samples | 155 | 21 | 133 |
| Peptides | 121 | 14 | 109 |
Function
CLDN6 · Claudin 6
Tight junctions represent one mode of cell-to-cell adhesion in epithelial or endothelial cell sheets, forming continuous seals around cells and serving as a physical barrier to prevent solutes and water from passing freely through the paracellular space. These junctions are comprised of sets of continuous networking strands in the outwardly facing cytoplasmic leaflet, with complementary grooves in the inwardly facing extracytoplasmic leaflet. This gene encodes a component of tight junction strands, which is a member of the claudin family. The protein is an integral membrane protein and is one of the entry cofactors for hepatitis C virus. The gene methylation may be involved in esophageal tumorigenesis. This gene is adjacent to another family member CLDN9 on chromosome 16.[provided by RefSeq, Aug 2010].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 116 amino-acid changes on canonical ENST00000328796 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in CLDN6 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in CLDN6 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 2/40 5% | 0/0 0% |
| Melanoma | 2/210 1% | 30/1899 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Germ Cell Tumour | 2/25 8% | 0/169 0% |
| Mesothelioma | 2/62 3% | 0/165 0% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 6/810 1% |
| Endometrial Carcinoma | 1/42 2% | 4/612 1% |
| Other Solid Cancers | 0/94 0% | 11/1515 1% |
| Cervical Carcinoma | 0/35 0% | 3/422 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Colorectal Carcinoma | 6/143 4% | 13/3239 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 8/1592 0% |
| Other Sarcomas | 0/69 0% | 3/699 0% |
| Ovarian Carcinoma | 0/109 0% | 4/998 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 3/1390 0% |
| Glioma | 0/52 0% | 7/2127 0% |
| Bladder Carcinoma | 0/58 0% | 3/956 0% |
| Small Cell Lung Carcinoma | 0/9 0% | 2/752 0% |
| Breast Carcinoma | 0/144 0% | 8/3264 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Pancreatic Carcinoma | 0/89 0% | 2/1611 0% |
| Head and Neck Carcinoma | 0/85 0% | 2/1574 0% |
| B-Cell Non-Hodgkins Lymphoma | 0/88 0% | 3/2534 0% |
| Biliary Tract Carcinoma | 0/54 0% | 1/950 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 2/2550 0% |
| Neuroblastoma | 0/87 0% | 1/1331 0% |
| Prostate Carcinoma | 0/13 0% | 1/2105 0% |
| Other Blood Cancers | 1/61 2% | 0/2725 0% |
Mutation Distribution
Where CLDN6 is mutated · all tissues, split by cell line vs tissue
How many mutations in CLDN6 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 48 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 325 mutations in CLDN6
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|